Could a Vitamin Be Effective Treatment for COPD?

Follow Drugslib on

Medically reviewed by Drugs.com.

By Carole Tanzer Miller HealthDay Reporter

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD, Danish researchers report.

"This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen, of the University of Copenhagen.

Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal.

The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo.

After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%.

"In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study."

More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said.

During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process.

NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging.

"As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking."

As such, he said NAD may be a target for future research and treatment.

Meanwhile, his team plans a larger study to confirm the initial findings.

"We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said.

Sources

  • University of Copenhagen, news release, Nov. 20, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-11-23 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords